Danielle Grieco, MD
Obstetrics & Gynecology · South Windsor, CTNPI 1104888304
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $619 and has fallen 74.8% since, to $156 in 2025.
Across 60 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$210
- Covidien LP$124
- Duchesnay USA Incorporated$88
- Vertical Pharmaceuticals, LLC$81
- Therapeuticsmd, Inc.$80
- Astellas Pharma US Inc$66
- plus $429 from 15 others
What the payments were for
- Food & beverage$1,05097%
- Education$283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $210 |
| Covidien LP | 7 | $124 |
| Duchesnay USA Incorporated | 4 | $88 |
| Vertical Pharmaceuticals, LLC | 5 | $81 |
| Therapeuticsmd, Inc. | 5 | $80 |
| Astellas Pharma US Inc | 3 | $66 |
| Avion Pharmaceuticals | 5 | $61 |
| Exeltis, USA Inc. | 3 | $56 |
| Coopersurgical, Inc. | 3 | $53 |
| Mayne Pharma Commercial LLC | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Pfizer | 2 | $25 |
| Davol Inc. | 1 | $23 |
| Myovant Sciences Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Amgen | 1 | $19 |
| Roche Diagnostics Corporation | 1 | $18 |
| Millicent US Inc | 1 | $17 |
| Merck | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,078 in reported general payments places this provider in the 70th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 41 | $2,175 |
| Clobetasol Propionate | 19 | $411 |
| Alendronate Sodium | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in South Windsor
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
- Mark LeondiresNorwalk$31K
- Alan FineHartford$30K
- Sean FlahertyHamden$28K
- Adam SteinbergHartford$23K
- Sarp AkselStamford$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.